SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Salvat

Status and phase: Completed; Phase 2

Conditions: Overactive Bladder (OAB)

Treatments: Drug: SVT-40776

Study type: Interventional

Funder types: Industry

Identifiers

NCT00507169

40776ORII/05IA01

Details and patient eligibility

About

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion criteria

• Pregnant and breastfeeding women
• Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind